Holen Sie sich die Stockscreener-App
4.57
4.94%
0.215
Handel nachbörslich:
4.76
0.19
+4.16%
Schlusskurs vom Vortag:
$4.355
Offen:
$4.42
24-Stunden-Volumen:
1.11M
Relative Volume:
0.87
Marktkapitalisierung:
$634.85M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.1658
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
-10.04%
1M Leistung:
-19.12%
6M Leistung:
-52.30%
1J Leistung:
-46.24%
1-Tages-Spanne:
$4.36
$4.63
1-Wochen-Bereich:
$4.155
$4.995
52-Wochen-Spanne:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
4.57 | 604.98M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
VIR Biotechnology’s SWOT analysis: stock outlook amid clinical trials and cash reserves - Investing.com
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - MSN
Vir Biotechnology’s Q2 2025: Unraveling Contradictions in ECLIPSE Trials, HDV Prevalence, and T-Cell Strategies - AInvest
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $12 to $31 - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript - Insider Monkey
Vir Biotechnology’s Earnings Call Highlights Progress and Challenges - TipRanks
Vir Biotechnology (VIR.O) Plunges 14.5%: What’s Driving the Intraday Swoon? - AInvest
Vir Biotechnology's 12.4% Intraday Drop: A Technical and Order-Flow Deep Dive - AInvest
Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips - Investing.com
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - BioSpace
Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum - MSN
Vir Biotechnology 2025 Q2 Earnings Losses Narrow 19.8% as Net Income Declines - AInvest
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Vir Biotechnology Reports Q2 2025 Financial Results - TipRanks
Vir Biotechnology's Q2 2025 Performance and Future Outlook: A Contrarian's Playbook for a Biotech Underdog - AInvest
Vir Biotechnology: A High-Conviction Play in Hepatitis Delta and Next-Gen Oncology Innovation - AInvest
Transcript : Vir Biotechnology, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Vir Biotechnology Q2 Earnings Fall Short of Estimates, Revenue Lags Behind - AInvest
Vir Biotechnology Q2 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. SEC 10-Q Report - TradingView
Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss - MarketScreener
Vir Biotechnology Q2 revenue misses expectations, net loss narrows - MarketScreener
Vir Biotechnology reports Q2 EPS (80c), consensus (72c) - TipRanks
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Press Release: Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
Vir Biotechnology enrolls first participant in ECLIPSE 3 trial - TipRanks
Vir Biotechnology successfully initiates all trials in Eclipse registrational program - MarketScreener
Vir Biotechnology completes initiation of hepatitis delta program By Investing.com - Investing.com Nigeria
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial - StreetInsider
Vir Biotechnology Director SATO VICKI L Sells 22000 Shares at $4.99/Share. - AInvest
How strong is Vir Biotechnology Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Is Vir Biotechnology Inc. a good long term investmentMaximize gains with data-driven stock picks - Jammu Links News
Vir Biotechnology initiates second pivotal trial in its global ECLIPSE registrational program for chronic hepatitis delta - European AIDS Treatment Group
Is Vir Biotechnology Inc. stock overvalued or undervaluedMaximize your returns with expert insights - Jammu Links News
What analysts say about Vir Biotechnology Inc. stockMassive stock growth - Jammu Links News
How does Vir Biotechnology Inc. generate profit in a changing economyConsistent double returns - Jammu Links News
Should I hold or sell Vir Biotechnology Inc. stock in 2025Discover high-impact stocks for your portfolio - Jammu Links News
Vir Biotechnology Inc. Stock Analysis and ForecastCapitalize on market trends with confidence - Jammu Links News
What are the latest earnings results for Vir Biotechnology Inc.Unlock exclusive stock market forecasts - Jammu Links News
What are Vir Biotechnology Inc. company’s key revenue driversUnmatched market performance - Jammu Links News
How many analysts rate Vir Biotechnology Inc. as a “Buy”Consistent triple returns - Jammu Links News
Published on: 2025-08-03 07:23:25 - Jammu Links News
When is Vir Biotechnology Inc. stock expected to show significant growthBuild a winning investment portfolio - Jammu Links News
Why is Vir Biotechnology Inc. stock attracting strong analyst attentionExceptional return forecasts - Jammu Links News
What are analysts’ price targets for Vir Biotechnology Inc. in the next 12 monthsUnlock powerful portfolio optimization tools - Jammu Links News
How does Vir Biotechnology Inc. compare to its industry peersBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
Vir Biotechnology Inc. Recovery Gathers Momentum on Chart SignalsLow Risk Equity Screener With Results Shared - metal.it
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):